应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BK4007 制药
未开盘 03-05 16:00:00 EST
851.65
-18.72
-2.15%
最高
869.97
最低
842.45
成交量
5.32亿
今开
869.97
昨收
870.38
日振幅
3.16%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
156.94亿
换手率
--
流通股本
0.00
市净率
5.403806
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
减重幅度达15.1% 辉瑞(PFE.US)减肥药“先维盈”在华获批
智通财经 · 15:14
减重幅度达15.1% 辉瑞(PFE.US)减肥药“先维盈”在华获批
辉瑞中国：埃诺格鲁肽获批用于中国成人体重管理
每日经济新闻 · 13:08
辉瑞中国：埃诺格鲁肽获批用于中国成人体重管理
21Shares 宣布 21Shares Polkadot ETF 即将在纳斯达克上线
链捕手 · 11:35
21Shares 宣布 21Shares Polkadot ETF 即将在纳斯达克上线
港股异动 | 创新药概念股走高，和黄医药涨超9%
老虎资讯综合 · 09:52
港股异动 | 创新药概念股走高，和黄医药涨超9%
港股通减肥药龙头！派格生物（02565）入围，能否挑战礼来全球市场地位？
智通财经 · 08:35
港股通减肥药龙头！派格生物（02565）入围，能否挑战礼来全球市场地位？
诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者
药研途 · 07:28
诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者
Contineum Therapeutics公司拟通过Leerink Partners发行A类普通股 募资额最高达1亿美元——SEC文件披露
美股速递 · 05:51
Contineum Therapeutics公司拟通过Leerink Partners发行A类普通股 募资额最高达1亿美元——SEC文件披露
Contineum Therapeutics公布2025年第四季度财务业绩，重申关键临床开发里程碑
美股速递 · 05:07
Contineum Therapeutics公布2025年第四季度财务业绩，重申关键临床开发里程碑
强生宣布Tecvayli®联合Darzalex Faspro®获美国FDA批准，用于复发/难治性多发性骨髓瘤，有望在二线治疗中树立新标准
美股速递 · 04:56
强生宣布Tecvayli®联合Darzalex Faspro®获美国FDA批准，用于复发/难治性多发性骨髓瘤，有望在二线治疗中树立新标准
Biofrontera Inc.盘中异动 股价大跌5.13%报0.850美元
市场透视 · 02:49
Biofrontera Inc.盘中异动 股价大跌5.13%报0.850美元
Gain Therapeutics, Inc.盘中异动 股价大跌5.06%
市场透视 · 01:49
Gain Therapeutics, Inc.盘中异动 股价大跌5.06%
Processa Pharmaceuticals, Inc.盘中异动 早盘急速拉升5.00%
市场透视 · 03-05 23:36
Processa Pharmaceuticals, Inc.盘中异动 早盘急速拉升5.00%
Inventiva Sa盘中异动 早盘急速拉升5.15%报6.33美元
市场透视 · 03-05 22:56
Inventiva Sa盘中异动 早盘急速拉升5.15%报6.33美元
Neurogene Inc.盘中异动 早盘股价大涨5.60%
市场透视 · 03-05 22:55
Neurogene Inc.盘中异动 早盘股价大涨5.60%
Jupiter Neurosciences, Inc.盘中异动 早盘股价大跌8.98%报0.412美元
市场透视 · 03-05 22:41
Jupiter Neurosciences, Inc.盘中异动 早盘股价大跌8.98%报0.412美元
Fibrobiologics, Inc.盘中异动 大幅上涨5.94%
市场透视 · 03-05 22:33
Fibrobiologics, Inc.盘中异动 大幅上涨5.94%
阿斯利康跌1.13% 股价跌破200美元大关
市场透视 · 03-05 22:31
阿斯利康跌1.13% 股价跌破200美元大关
瑞幸大股东收购蓝瓶咖啡，重返纳斯达克又近一步?
蓝鲸财经 · 03-05 22:05
瑞幸大股东收购蓝瓶咖啡，重返纳斯达克又近一步?
礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争
环球市场播报 · 03-05 21:39
礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争
礼来(LLY.US)减重新药在中国获批关键3期临床
智通财经 · 03-05 21:12
礼来(LLY.US)减重新药在中国获批关键3期临床
公司概况
公司名称：
制药
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"BK4007","market":"US","secType":"PLATE","nameCN":"制药","latestPrice":851.65466,"timestamp":1772744399999,"preClose":870.37555,"halted":0,"volume":531569273,"delay":0,"changeRate":-0.021509,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-18.720886,"latestTime":"03-05 16:00:00 EST","open":869.9685,"high":869.9685,"low":842.4515,"amount":15694396784.653923,"amplitude":0.031615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772807400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.403806,"peRate":26.396264,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4007/wiki","defaultTab":"wiki","newsList":[{"id":"2617077745","title":"减重幅度达15.1% 辉瑞(PFE.US)减肥药“先维盈”在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2617077745","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617077745?lang=zh_cn&edition=full","pubTime":"2026-03-06 15:14","pubTimestamp":1772781254,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国已正式批准美国制药巨头辉瑞公司旗下的GLP-1类治疗药物——埃诺格鲁肽注射液，用于超重或肥胖成年人的长期体重管理。这一获批标志着辉瑞在中国代谢疾病领域迈出了战略性的一步。然而，针对定价以及产品在中国上市的具体日期等问题，辉瑞公司发言人未立即作出回应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"减重幅度达15.1% 辉瑞(PFE.US)减肥药“先维盈”在华获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225284248.USD","SG9999002224.SGD","SG9999001176.USD","LU0225771236.USD","LU0058720904.USD","LU1894683264.USD","IE00BLSP4452.SGD","LU1023059063.AUD","LU0306807586.USD","LU0985481810.HKD","BK4599","BK4550","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU1894683348.USD","PFE","LU1883839398.USD","LU1057294990.SGD","LU0289739699.SGD","BK4568","LU0122379950.USD","IE00B19Z3581.USD","LU0234572021.USD","SG9999002232.USD","BK4592","BK4588","BK4533","BK4007","LU0868494617.USD","BK4581","LU0170899867.USD","SG9999001176.SGD","SG9999003800.SGD","LU1066051498.USD","LU0321505868.SGD","IE00BBT3K403.USD","BK4534","SG9999013999.USD","IE0002270589.USD","LU0321505439.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","SG9999011175.SGD","BK4585","LU0456855351.SGD","LU0306806265.USD","LU1066053197.SGD"],"gpt_icon":0},{"id":"2617504424","title":"辉瑞中国：埃诺格鲁肽获批用于中国成人体重管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2617504424","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617504424?lang=zh_cn&edition=full","pubTime":"2026-03-06 13:08","pubTimestamp":1772773717,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月6日，辉瑞中国在官微宣布，国家药品监督管理局（NMPA）已正式批准新一代cAMP偏向型GLP-1受体激动剂埃诺格鲁肽注射液（先维盈?），用于在控制饮食和增加体力活动基础上对成人超重/肥胖患者的长期体重管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603063664304562.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603063664304562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001176.USD","IE00B19Z3B42.SGD","BK4007","LU0868494617.USD","BK4588","LU1057294990.SGD","LU0225284248.USD","SG9999001176.SGD","LU0985481810.HKD","LU1066053197.SGD","BK4568","BK4533","SG9999011175.SGD","IE0002270589.USD","BK4585","IE00BLSP4452.SGD","SG9999003800.SGD","BK4581","LU0306807586.USD","BK4534","BK4592","LU1883839398.USD","BK4550","LU0058720904.USD","LU0170899867.USD","SG9999002232.USD","LU1894683348.USD","LU0306806265.USD","LU1894683264.USD","LU0122379950.USD","SG9999013999.USD","IE00B19Z3581.USD","BK4599","LU0321505439.SGD","IE00BLSP4239.USD","LU0234572021.USD","LU0456855351.SGD","PFE","LU0321505868.SGD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1066051498.USD","LU0289739699.SGD","LU1023059063.AUD","SG9999002224.SGD","IE000M9KFDE8.USD","LU0225771236.USD"],"gpt_icon":0},{"id":"2617509158","title":"21Shares 宣布 21Shares Polkadot ETF 即将在纳斯达克上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2617509158","media":"链捕手","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617509158?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:35","pubTimestamp":1772768152,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方消息，21Shares US 宣布其 Polkadot 现货 ETF——21Shares Polkadot ETF（股票代码：TDOT）将于明日在纳斯达克上线。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2249998","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEPQ","NVIW.SI","PSQ","QQQY","USJW.SI","GPIQ","QID","QQQJ","BK4588","TSYW.SI","QYLD","MNQmain","TQQQ","BK4007","QLD","BK4550","QYLG","BK1147","QQQE","SQQQ","USAW.SI","BK4585"],"gpt_icon":0},{"id":"1143743897","title":"港股异动 | 创新药概念股走高，和黄医药涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143743897","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143743897?lang=zh_cn&edition=full","pubTime":"2026-03-06 09:52","pubTimestamp":1772761971,"startTime":"0","endTime":"0","summary":"3月6日，港股创新药概念股集体走高，$和黄医药(00013)$涨超9%，$三生制药(01530)$涨超7%，$四环医药(00460)$、$信达生物(01801)$、$恒瑞医药(600276)$、$康方生物(09926)$跟涨。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1191","BK4007","00013","BK1574","BK4531","BK4585","BK1161","BK1587","BK1588"],"gpt_icon":0},{"id":"2617994508","title":"港股通减肥药龙头！派格生物（02565）入围，能否挑战礼来全球市场地位？","url":"https://stock-news.laohu8.com/highlight/detail?id=2617994508","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617994508?lang=zh_cn&edition=full","pubTime":"2026-03-06 08:35","pubTimestamp":1772757357,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年开年港股市场最受关注的名单重磅出炉，3月9日起，派格生物医药正式进入港股通。派格生物的派达康在这一点上表现较为突出。相关临床数据显示，其药物相关胃肠道不良事件发生率低于7%。就在派格生物入围港股通的同时，跨国药企在减重赛道上的军备竞赛已进入白热化阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0353189763.USD","LU1712237335.SGD","LU0106261372.USD","LU2087625088.SGD","LLII","IE00BK4W5M84.HKD","LU0225283273.USD","BK4533","BK4588","LU2089284900.SGD","LU2471134523.USD","LU0432979614.USD","LU0354030511.USD","LU2168564495.EUR","LU2456880835.USD","LU2491050071.SGD","SGXZ99366536.SGD","IE00BKPKM429.USD","LU0320765992.SGD","IE00B1BXHZ80.USD","LU0158827948.USD","LU0823434583.USD","LU2750360641.GBP","LU0882574139.USD","SG9999001176.SGD","LU2552382132.HKD","LU2265009873.SGD","LU1623119135.USD","LU0109391861.USD","LU2360106947.USD","LU1548497426.USD","LU2357305700.SGD","LLY","LU0353189680.USD","LU2361044865.SGD","LU0823434740.USD","LU2168564149.EUR","LU2552382215.SGD","LU0672654240.SGD","LU1551013425.SGD","LU0820561909.HKD","LU2237443382.USD","LU2271345857.HKD","LU0786609619.USD","SG9999015986.USD","LU1127390331.HKD","IE00B4R5TH58.HKD","LU0256863811.USD","LU1366192091.USD","LU2756315318.SGD","LU1983299246.USD","LU0417517546.SGD","LU1093756168.USD","LU1804176565.USD","LU0471298777.SGD","LU0316494557.USD","LU2462157665.USD","LU0471298694.HKD","LU2111349929.HKD","SG9999014898.SGD","SG9999018857.SGD","SG9999018865.SGD","LU2112291526.USD","LU0006306889.USD","LU0456855351.SGD","LU2361044949.HKD","LU0882574055.USD","LU0320765059.SGD","LU0385154629.USD","IE00BKDWB100.SGD","LU1917777945.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4599","IE00BFTCPJ56.SGD","IE0002141913.USD","LU2213496289.HKD","LU0289739699.SGD","LU1629891620.HKD","LU0323591593.USD","LU1145028129.USD","LU0964807845.USD","LU0689472784.USD","SG9999014880.SGD","LU2461242641.AUD","LU1035775433.USD","LU2168564222.USD","LU0094547139.USD","LU0158827781.USD","LU2023250330.USD","LU2552382058.USD","LU0114720955.EUR","LU2896262040.SGD","SG9999017495.SGD","LU2237443978.SGD","LU2471134879.HKD","LU1061106388.HKD","LU2491050154.USD","LU2756315664.SGD","SG9999015945.SGD","IE00B4JS1V06.HKD","LU1868836591.USD","LU0122379950.USD","LU0256863902.USD","SG9999015978.USD","LU1057294990.SGD","IE00BK4W5L77.USD","IE00BFSS7M15.SGD","IE00BJJMRY28.SGD","LU0708995401.HKD","ELIS","SG9999013999.USD","IE0004445015.USD","ELIL","LU2168564065.EUR","LU1868836757.USD","LU0640476718.USD","LU0061475181.USD","SGXZ31699556.SGD","IE0004445239.USD","IE00B7KXQ091.USD","BK4585","LU1868837300.USD","IE00BJT1NW94.SGD","LU1868836914.USD","GB00BDT5M118.USD","LU0889565916.HKD","LU0109394709.USD","LU1551013342.USD","LU0820562030.AUD","02565","BK4581","LU2237443549.SGD","IE0005OL40V9.USD","LU2468319806.SGD","LU2089283258.USD","LU2324357040.USD","LU1868837136.USD","LU0820561818.USD","LU2089984988.USD","BK4534","LU2023250504.SGD","IE00BJLML261.HKD","LU0198837287.USD","LU2750360997.AUD","LU0354030438.USD","LU1291159041.SGD","LU0238689110.USD","LU2237443895.HKD","LU2602419157.SGD","LU1720051017.SGD","IE0009355771.USD","LU0058720904.USD","LU1323610961.USD","LU1974910355.USD","SG9999014914.USD","LU2417539215.USD","LU1267930730.SGD","LU2264538146.SGD","SGXZ51526630.SGD","LU0079474960.USD","LU1093756325.SGD","LU1814569148.SGD","LU2063271972.USD","LU2471134952.CNY","SG9999014906.USD","LU1989771016.USD","SG9999001176.USD","LU0203202063.USD","LU0203201768.USD","LU2237438978.USD","LU2236285917.USD","LU0943347566.SGD","LU1280957306.USD","BK4007","LLYZ","LU2237443622.USD","LU1064131342.USD","LU1988902786.USD","LU2746668461.USD","LU1720051108.HKD","LU2471134796.USD","LU0096364046.USD","IE0001KFT4U8.USD","SGXZ57979304.SGD","LU2361045086.USD","LU0466842654.USD","LU0210536198.USD","IE00BFSS8Q28.SGD","LU1069344957.HKD","LLYX","LU2023251221.USD","IE00B775H168.HKD","IE00BJJMRX11.SGD","LU0097036916.USD","LU0683600562.USD","LU1232071149.USD","LU2237443465.HKD","IE00B1XK9C88.USD","LU0234572021.USD","LU2028103732.USD","BK4516","SGXZ81514606.USD","SG9999015952.SGD","LU2108987350.USD","LU2106854487.HKD","BK1161","LU1023059063.AUD","IE00BWXC8680.SGD","LU0787776722.HKD","LU0823416689.USD","LU2746668974.SGD","LU2491049909.HKD","LU0266013472.USD","LU2168563687.JPY","LU2211815571.USD","IE00BN29S564.USD"],"gpt_icon":1},{"id":"2617577411","title":"诺和诺德“司美格鲁肽”治疗MASH拟纳入优先审评，即将惠及国内广大MASH患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577411","media":"药研途","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577411?lang=zh_cn&edition=full","pubTime":"2026-03-06 07:28","pubTimestamp":1772753310,"startTime":"0","endTime":"0","summary":"2026年3 月 3 日，CDE 官网显示，诺和诺德“司美格鲁肽注射液”新适应症在国内申报上市，并拟纳入优先审评，适应症为：用于治疗代谢相关脂肪性肝炎伴中重度肝纤维化的非肝硬化成人患者。全球约有2.5亿MASH患者，其中超过三分之一的超重或肥胖人群同时患有MASH，疾病负担日益加重。司美格鲁肽治疗MASH的作用机制司美格鲁肽通过多重直接与间接途径改善MASH病理进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306074632a4518566&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOH","LU1093756168.USD","BK4599","NVO","NVOX","BK4588","LU0154236417.USD","BK4585"],"gpt_icon":1},{"id":"1160802484","title":"Contineum Therapeutics公司拟通过Leerink Partners发行A类普通股 募资额最高达1亿美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1160802484","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160802484?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:51","pubTimestamp":1772747498,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会（SEC）最新公开的文件显示，生物制药企业Contineum Therapeutics Inc.已启动一项新股发行计划。该公司拟通过承销商Leerink Partners，向市场公开发行其A类普通股，此次募资规模最高可达1亿美元。\n此次融资计划旨在为公司的临床阶段研发项目提供资金支持，进一步推进其神经系统疾病治疗药物的开发进程。具体发行条款，包括发行价格、股票数量及最终募资规模，将根据市场情况最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"1119669221","title":"Contineum Therapeutics公布2025年第四季度财务业绩，重申关键临床开发里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1119669221","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119669221?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:07","pubTimestamp":1772744832,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics（股票代码：CTNM）已正式披露其2025年第四季度的财务报告。公司同时确认，其核心临床开发项目正按计划推进，关键里程碑节点保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"1189059267","title":"强生宣布Tecvayli®联合Darzalex Faspro®获美国FDA批准，用于复发/难治性多发性骨髓瘤，有望在二线治疗中树立新标准","url":"https://stock-news.laohu8.com/highlight/detail?id=1189059267","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189059267?lang=zh_cn&edition=full","pubTime":"2026-03-06 04:56","pubTimestamp":1772744173,"startTime":"0","endTime":"0","summary":"强生公司宣布，其Tecvayli®联合Darzalex Faspro®的治疗方案已获得美国食品药品监督管理局（FDA）的批准，用于治疗复发或难治性多发性骨髓瘤患者。\n这一批准意义重大，因为它为患者提供了一种潜在的全新护理标准，该方案甚至可在疾病的第二线治疗阶段就尽早使用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1221951046.USD","IE0034235303.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","LU0234572021.USD","LU1221951129.SGD","LU0985320562.USD","LU1585245621.USD","IE00BZ1G4Q59.USD","LU1929549753.HKD","LU1674673691.USD","IE00BDGV0183.EUR","BK4532","BK4559","IE00B2B36J28.USD","IE00BSNM7G36.USD","LU0070217475.USD","LU0787776722.HKD","LU2471134796.USD","JNJ","LU2129689514.USD","LU0889566641.SGD","IE00B7SZLL34.SGD","LU2112291526.USD","LU1066051225.USD","IE00BBT3K403.USD","LU0795875169.SGD","IE00B3PB1722.GBP","LU2471134879.HKD","LU2430703095.HKD","LU1066051498.USD","LU1061106388.HKD","LU2430703178.SGD","LU2471134523.USD","LU1496350502.SGD","LU1066051811.HKD","LU0640476718.USD","LU1718418525.SGD","BK4533","IE00BGHQF631.EUR","LU0058720904.USD","LU2347655156.SGD","SG9999001440.SGD","LU2133065610.SGD","LU1261432733.SGD","LU2430703251.USD","SG9999002224.SGD","IE00BFXG1179.USD","BK4534","LU0683600562.USD","LU1059921491.USD","IE00B1BXHZ80.USD","IE00BLSP4452.SGD","LU1057294990.SGD","LU0882574055.USD","LU1674673428.USD","LU2750360997.AUD","LU2602419157.SGD","IE00BVYPNW00.USD","BK4581","LU1935042991.SGD","IE0002270589.USD","LU1196500208.SGD","LU1732799900.SGD","LU0234570918.USD","LU0345770993.USD","LU0345769128.USD","LU1023059063.AUD","LU0320765646.SGD","IE00B19Z3B42.SGD","LU1244550494.USD","LU0203345920.USD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU1983299246.USD","LU1430594728.SGD","LU2505996681.GBP","LU0466842654.USD","IE00B3T34201.USD","LU0124676726.USD","LU2129689431.USD","IE0009355771.USD","LU2750360641.GBP","LU0689626769.HKD","LU1032955483.USD","LU0122379950.USD","LU1267930813.SGD","LU1066053197.SGD","LU1162221912.USD","LU2468319806.SGD","LU0912757837.SGD","IE00BJJMRZ35.SGD","IE00BLSP4239.USD","BK4504","IE00BKVL7J92.USD","BK4588","LU0345769631.USD","SG9999002232.USD","LU0345770308.USD","LU0114720955.EUR","LU2129689605.HKD","LU1074936037.SGD","IE00B42XCP33.USD","LU2471134952.CNY","LU1894683264.USD","IE0002141913.USD","LU1732800096.USD","LU2592432038.USD","LU0203347892.USD","BK4568","LU0098860793.USD","LU1032466523.USD","LU1914381329.SGD","LU2505996509.AUD","LU2089984988.USD","LU1244550221.USD","BK4585","LU1894683348.USD","IE00BJT1NW94.SGD","LU1506573853.SGD","LU0795875086.SGD","LU1244550577.SGD","LU0792757196.USD","IE000M9KFDE8.USD","BK4550","IE0001KFT4U8.USD","IE00BVYPNV92.GBP","BK4007","LU1280957306.USD","BK4592","LU1778281490.HKD","IE00BFTCPJ56.SGD","LU0432979614.USD"],"gpt_icon":0},{"id":"2617557423","title":"Biofrontera Inc.盘中异动 股价大跌5.13%报0.850美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617557423","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617557423?lang=zh_cn&edition=full","pubTime":"2026-03-06 02:49","pubTimestamp":1772736556,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日02时49分，Biofrontera Inc.股票出现异动，股价快速下跌5.13%。截至发稿，该股报0.850美元/股，成交量1.629万股，换手率0.14%，振幅4.02%。Biofrontera Inc.股票所在的制药行业中，整体跌幅为2.58%。Biofrontera Inc.公司简介：Biofrontera Inc 是一家总部位于美国的生物制药公司，专注于商业化一系列用于治疗皮肤科疾病的药物产品，特别关注光动力疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603060249179543335c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603060249179543335c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BFRI","BK4007"],"gpt_icon":0},{"id":"2617180527","title":"Gain Therapeutics, Inc.盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617180527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617180527?lang=zh_cn&edition=full","pubTime":"2026-03-06 01:49","pubTimestamp":1772732944,"startTime":"0","endTime":"0","summary":"北京时间2026年03月06日01时49分，Gain Therapeutics, Inc.股票出现异动，股价快速跳水5.06%。Gain Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.11%。Gain Therapeutics, Inc.公司简介：Gain Therapeutics Inc是一家生物技术公司，开发新型小分子疗法，用于治疗多个治疗领域的疾病，包括溶酶体储存疾病、中枢神经系统疾病、代谢疾病和肿瘤疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306014904a450c0b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306014904a450c0b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","GANX","BK4539","BK4139","BK4007"],"gpt_icon":0},{"id":"2617576251","title":"Processa Pharmaceuticals, Inc.盘中异动 早盘急速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576251","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617576251?lang=zh_cn&edition=full","pubTime":"2026-03-05 23:36","pubTimestamp":1772725000,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日23时36分，Processa Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.00%。Processa Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.65%。其相关个股中，Impact Biomedical, Inc.、Ensysce Biosciences, Inc.、Tenaya Therapeutics, Inc.涨幅较大，Quince Therapeutics, Inc.、Impact Biomedical, Inc.、Ensysce Biosciences, Inc.较为活跃，换手率分别为334.82%、145.86%、57.45%，振幅较大的相关个股有Ensysce Biosciences, Inc.、Impact Biomedical, Inc.、Tenaya Therapeutics, Inc.，振幅分别为49.85%、37.84%、33.32%。Processa Pharmaceuticals, Inc.公司简介：Processa Pharmaceuticals Inc是一家临床阶段的生物制药公司，专注于利用其监管科学方法开发下一代化疗肿瘤药物产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030523364095433116&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030523364095433116&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCSA","BK4007"],"gpt_icon":0},{"id":"2617509673","title":"Inventiva Sa盘中异动 早盘急速拉升5.15%报6.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617509673","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617509673?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:56","pubTimestamp":1772722594,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时56分，Inventiva Sa股票出现异动，股价快速上涨5.15%。截至发稿，该股报6.33美元/股，成交量3.5611万股，换手率0.02%，振幅3.41%。Inventiva Sa股票所在的生物技术行业中，整体跌幅为1.17%。Inventiva Sa公司简介：Inventiva SA 是一家总部位于法国的生物制药公司，专门开发影响核受体、转录因子和表观遗传调节的药物。该公司专注于开发其候选产品 lanifibranor，用于治疗非酒精性脂肪性肝炎或 NASH 患者，这种疾病目前尚无批准的治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305225634a4505241&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305225634a4505241&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBO","BK4139","IVA","BK4007"],"gpt_icon":0},{"id":"2617522010","title":"Neurogene Inc.盘中异动 早盘股价大涨5.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617522010","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617522010?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:55","pubTimestamp":1772722522,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时55分，Neurogene Inc.股票出现异动，股价快速拉升5.60%。截至发稿，该股报25.25美元/股，成交量4.4953万股，换手率0.29%，振幅5.27%。Neurogene Inc.股票所在的生物技术行业中，整体跌幅为1.21%。其相关个股中，Impact Biomedical, Inc.、Citius Pharmaceuticals, Inc.、Osr Holdings, Inc.涨幅较大，Quince Therapeutics, Inc.、Impact Biomedical, Inc.、Can Fite Biopharma Ltd较为活跃，换手率分别为309.95%、129.01%、35.13%，振幅较大的相关个股有Impact Biomedical, Inc.、Osr Holdings, Inc.、Moolec Science Sa C/Wts 30/01/2028，振幅分别为31.38%、27.56%、27.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305225522a6a7328d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305225522a6a7328d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","NGNE","IBO"],"gpt_icon":0},{"id":"2617203985","title":"Jupiter Neurosciences, Inc.盘中异动 早盘股价大跌8.98%报0.412美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617203985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617203985?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:41","pubTimestamp":1772721694,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时41分，Jupiter Neurosciences, Inc.股票出现异动，股价大幅跳水8.98%。截至发稿，该股报0.412美元/股，成交量9811股，换手率0.03%，振幅4.30%。Jupiter Neurosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.11%。Jupiter Neurosciences, Inc.公司简介：Jupiter Neurosciences Inc 是一家位于佛罗里达州朱庇特的临床阶段研发制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522413495432ed5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522413495432ed5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","JUNS"],"gpt_icon":0},{"id":"2617578712","title":"Fibrobiologics, Inc.盘中异动 大幅上涨5.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578712","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617578712?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:33","pubTimestamp":1772721185,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时33分，Fibrobiologics, Inc.股票出现波动，股价急速上涨5.94%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522330695432e4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030522330695432e4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139","IBO","BK4007"],"gpt_icon":0},{"id":"2617577596","title":"阿斯利康跌1.13% 股价跌破200美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2617577596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617577596?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:31","pubTimestamp":1772721101,"startTime":"0","endTime":"0","summary":"北京时间2026年03月05日22时31分，阿斯利康股票出现波动，股价快速下挫1.13%。截至发稿，该股报199.26美元/股，成交量3.4768万股，换手率0.00%，振幅0.25%。最近的财报数据显示，该股实现营业收入587.39亿美元，净利润102.25亿美元，每股收益6.60美元，毛利438.47亿美元，市盈率30.47倍。机构评级方面，在所有31家参与评级的机构中，81%的券商给予买入建议，10%的券商给予持有建议，9%的券商给予卖出建议。阿斯利康股票所在的制药行业中，整体跌幅为1.21%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305223141a6a71f62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305223141a6a71f62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU0109394709.USD","BK4568","LU2236285917.USD","LU0289739699.SGD","LU2462157665.USD","LU2456880835.USD","LU0058720904.USD","AZN","BK4588","LU2417539215.USD","IE00B3T34201.USD","LU1829250122.USD","BK4585","LU0320765992.SGD","BK4007"],"gpt_icon":0},{"id":"2617235055","title":"瑞幸大股东收购蓝瓶咖啡，重返纳斯达克又近一步?","url":"https://stock-news.laohu8.com/highlight/detail?id=2617235055","media":"蓝鲸财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617235055?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:05","pubTimestamp":1772719530,"startTime":"0","endTime":"0","summary":"2022年，蓝瓶首次进入中国，首店开在上海。对大钲资本而言，收购蓝瓶或许是瑞幸迂回纳斯达克的关键一步。大钲目前持有瑞幸23.28%的股份，掌握53.6%的投票权，是瑞幸的实际控制方。收购蓝瓶，正是回应这两个问题的关键落子。瑞幸目前拥有超过3万家门店，主打性价比，客单价相对固定。若黎辉能最终推动瑞幸重返纳斯达克，这不仅是一家企业的重生，更是其投资生涯中的最高光时刻。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1772679931012147527","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4610","BK4209","MNQmain","QYLG","NVIW.SI","TSYW.SI","LKNCY","BK1147","USAW.SI","SQQQ","QID","BK4007","GPIQ","JEPQ","QQQE","QQQJ","QLD","QQQY","PSQ","NQmain","QYLD","TQQQ","USJW.SI"],"gpt_icon":1},{"id":"2617254074","title":"礼来瞄准雇主GLP-1覆盖 以与诺和诺德竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254074","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254074?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:39","pubTimestamp":1772717940,"startTime":"0","endTime":"0","summary":"礼来公司推出“Employer Connect”，为新型多剂量Zepbound提供每月449美元的净价格，并与Teladoc Health和GoodRx等合作伙伴整合，以扩大肥胖药物的可及性；诺和诺德仍是主要竞争对手。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-05/doc-inhpycce3059268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0225283273.USD","BK4144","LU0316494557.USD","LU0672654240.SGD","LLYZ","LU2063271972.USD","BK4533","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU2028103732.USD","IE00BFTCPJ56.SGD","LU0471298777.SGD","LU2471134952.CNY","LU0158827948.USD","LU0109391861.USD","LU2111349929.HKD","NVO","LU2237443465.HKD","LU2468319806.SGD","LU2756315318.SGD","LU1868836757.USD","LU1291159041.SGD","LU0820561909.HKD","LU1989771016.USD","LU0820562030.AUD","LU0353189680.USD","LU2168564065.EUR","LU2361044865.SGD","LU2471134879.HKD","LU2552382215.SGD","LU0471298694.HKD","LU0354030438.USD","LU0198837287.USD","LU0964807845.USD","SGXZ57979304.SGD","LU0096364046.USD","LU0354030511.USD","LU0097036916.USD","LU2264538146.SGD","BK4581","LU2168564495.EUR","LU2237443895.HKD","SGXZ51526630.SGD","LU1868836914.USD","LU1804176565.USD","LU2112291526.USD","SG9999014914.USD","LU0323591593.USD","LU2750360641.GBP","LU0256863902.USD","SGXZ99366536.SGD","IE0001KFT4U8.USD","LU2236285917.USD","IE00BK4W5M84.HKD","LU0689472784.USD","LU0058720904.USD","LU2324357040.USD","IE00BKDWB100.SGD","LU1988902786.USD","LU1035775433.USD","SG9999001176.SGD","LU0823434740.USD","IE00B2B36J28.USD","LU1629891620.HKD","LU2168563687.JPY","LU2237443549.SGD","IE0009355771.USD","BK4588","LU1323610961.USD","BK4585","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU2417539215.USD","LU2491050071.SGD","IE0004445239.USD","NVOX","SG9999014898.SGD","LU1061106388.HKD","LU2089284900.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0823416689.USD","LU1720051017.SGD","SG9999015945.SGD","LU0289739699.SGD","LU1623119135.USD","LU2211815571.USD","LU2213496289.HKD","SG9999015952.SGD","IE00BN29S564.USD","LU2552382058.USD","IE0004445015.USD","LU1814569148.SGD","LU1868837300.USD","LU2087625088.SGD","LU1069344957.HKD","SG9999015986.USD","LU2023250504.SGD","LU1720051108.HKD","BK4007","LU1551013342.USD","BK4599","LU1548497426.USD","LU2602419157.SGD","LU0238689110.USD","IE0002141913.USD","IE00B1XK9C88.USD","SG9999001176.USD","LU2237443382.USD","SG9999017495.SGD","LU0787776722.HKD","LU0353189763.USD","LU0417517546.SGD","LU2108987350.USD","LU1551013425.SGD","LU0256863811.USD","BK4534","LU2456880835.USD","LU0203201768.USD","LU1093756325.SGD","LU2023251221.USD","LU0210536198.USD","LU2271345857.HKD","SG9999013999.USD","SG9999018865.SGD","LU2089984988.USD","LU1232071149.USD","LU1093756168.USD","LU0683600562.USD","LU0385154629.USD","LU2750360997.AUD","LU2471134796.USD","LU2361044949.HKD","LU0786609619.USD","LU0106261372.USD","LU1868837136.USD","LU2089283258.USD","LU0320765992.SGD","LU2237443622.USD","LU0889565916.HKD","LU0114720955.EUR","LU1983299246.USD","LU2361045086.USD","SG9999014906.USD","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU2168564149.EUR","SG9999015978.USD","LU2461242641.AUD","LU0943347566.SGD","LU0203202063.USD","NVOH","LU1127390331.HKD","LU0006306889.USD","LU2896262040.SGD","LU0820561818.USD","IE00BJT1NW94.SGD","LU0079474960.USD","LU2746668461.USD","LU2746668974.SGD","IE00B4JS1V06.HKD","LU0466842654.USD","LU2471134523.USD","BK4590","LU0234572021.USD","LU2357305700.SGD","LU0154236417.USD","LU1280957306.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2360106947.USD","LU0882574139.USD","LU2552382132.HKD","IE00BK4W5L77.USD","LU0061475181.USD","LU2237443978.SGD","BK4516","LU2491049909.HKD","LU1057294990.SGD","LU2237438978.USD","IE00BJJMRY28.SGD","LU0882574055.USD","LU1145028129.USD","GB00BDT5M118.USD","LU0094547139.USD","BK4532","IE00BKPKM429.USD","ELIL","LU2023250330.USD","LLY","SG9999014880.SGD","IE00BFSS7M15.SGD","LU2168564222.USD","SG9999018857.SGD","IE00B7KXQ091.USD","IE00BJLML261.HKD","ELIS","SGXZ81514606.USD","IE00BKVL7J92.USD","LU0708995401.HKD","LU2491050154.USD","IE00B775H168.HKD","LLII","LU0456855351.SGD","LU1974910355.USD","LU2462157665.USD","IE0005OL40V9.USD","LU1064131342.USD","LU2106854487.HKD","LU0158827781.USD","IE00BJJMRX11.SGD","LU0432979614.USD","LU1868836591.USD","IE00BFSS8Q28.SGD","LU2265009873.SGD","LU1366192091.USD","LU0109394709.USD","LU2756315664.SGD","LLYX","LU0320765059.SGD","LU0640476718.USD","LU1917777945.USD","LU0266013472.USD","LU0823434583.USD"],"gpt_icon":0},{"id":"2617547054","title":"礼来(LLY.US)减重新药在中国获批关键3期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547054","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617547054?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:12","pubTimestamp":1772716361,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近期，礼来宣布，新型长效胰淀素受体激动剂eloralintide获中国国家药品监督管理局药品审评中心批准，同步在中国开展3项全球关键3期临床研究，用于支持未来该产品在体重管理等多个适应症在中国的注册，以满足肥胖或超重患者及其相关合并症患者的临床需求，提供更多有效且耐受性良好的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"礼来(LLY.US)减重新药在中国获批关键3期临床","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B775H168.HKD","LLII","LU0316494557.USD","LU1551013342.USD","IE00B4JS1V06.HKD","LU0094547139.USD","LU0672654240.SGD","LU2360106947.USD","LU2456880835.USD","LU2106854487.HKD","IE00B7KXQ091.USD","LU2028103732.USD","LU0289739699.SGD","LU2237438978.USD","LU2023250330.USD","LU2168564495.EUR","IE00BJT1NW94.SGD","LU1093756325.SGD","LU0471298694.HKD","LU0786609619.USD","IE00BJLML261.HKD","LU2168563687.JPY","LU0109394709.USD","LU2237443382.USD","LU0203201768.USD","LU1804176565.USD","LU1035775433.USD","SG9999015952.SGD","LU2211815571.USD","LU2471134879.HKD","LU2552382058.USD","LU2491050071.SGD","IE00BK4W5M84.HKD","SG9999014914.USD","LU1720051108.HKD","ELIL","LU0683600562.USD","LU0109391861.USD","LU0061475181.USD","BK4588","IE00BKPKM429.USD","LU0417517546.SGD","SG9999015945.SGD","SG9999015986.USD","LU0385154629.USD","LU2111349929.HKD","LU2461242641.AUD","IE00BFTCPJ56.SGD","SGXZ51526630.SGD","LLY","IE00B2B36J28.USD","LU0354030511.USD","IE00BJJMRY28.SGD","LU0323591593.USD","IE00BJJMRZ35.SGD","LU0640476718.USD","LU0689472784.USD","LU0203202063.USD","LU0320765992.SGD","LU0943347566.SGD","LU2361044949.HKD","LU1267930730.SGD","LU2361045086.USD","LU1988902786.USD","LU2552382132.HKD","LU0320765059.SGD","LU2087625088.SGD","LU2471134796.USD","LU0353189680.USD","LU2168564222.USD","LU2168564065.EUR","LU2237443549.SGD","LU2552382215.SGD","LU0256863902.USD","IE00BWXC8680.SGD","LU1366192091.USD","LU0820561818.USD","BK4516","SG9999018857.SGD","LU0820561909.HKD","LU0432979614.USD","LU2491050154.USD","LU1064131342.USD","LU2236285917.USD","LU2108987350.USD","SG9999014898.SGD","LU2237443978.SGD","LU2756315318.SGD","LU2471134952.CNY","IE00BKDWB100.SGD","LU2491049909.HKD","SG9999017495.SGD","LU1323610961.USD","BK4534","IE0001KFT4U8.USD","LU2089284900.SGD","LU1280957306.USD","SG9999014906.USD","IE00BJJMRX11.SGD","SGXZ31699556.SGD","LU0238689110.USD","LU2417539215.USD","LU2602419157.SGD","IE00B4R5TH58.HKD","LU1127390331.HKD","LU2750360641.GBP","BK4533","IE0004445239.USD","LU0106261372.USD","LU0823434583.USD","SG9999013999.USD","LU0787776722.HKD","LU0823434740.USD","IE0004445015.USD","LU0158827781.USD","SGXZ99366536.SGD","GB00BDT5M118.USD","LU0964807845.USD","LU2089283258.USD","LU2237443465.HKD","BK4581","LU2361044865.SGD","LU1868836591.USD","LLYZ","LU1023059063.AUD","LU1974910355.USD","LU0354030438.USD","IE0002141913.USD","LU2462157665.USD","SG9999001176.SGD","IE00BFSS8Q28.SGD","LU0882574055.USD","LU0122379950.USD","SGXZ57979304.SGD","LU1989771016.USD","LU2168564149.EUR","LU0234572021.USD","LU2756315664.SGD","LU0225283273.USD","LU1551013425.SGD","LU2746668974.SGD","LU0096364046.USD","LU0820562030.AUD","LU2264538146.SGD","ELIS","LU1232071149.USD","LU2237443895.HKD","LU2750360997.AUD","LU2089984988.USD","LU0079474960.USD","LU0708995401.HKD","LU0210536198.USD","LU0158827948.USD","LU1623119135.USD","LU1868837136.USD","LU0006306889.USD","LU1061106388.HKD","LU2237443622.USD","SG9999018865.SGD","LU2471134523.USD","LU2896262040.SGD","LU1983299246.USD","LU0353189763.USD","LU0466842654.USD","LU1057294990.SGD","LU1712237335.SGD","LU1291159041.SGD","LU1917777945.USD","LU2023250504.SGD","LU0114720955.EUR","LU2746668461.USD","LU0198837287.USD","LU1720051017.SGD","LU2265009873.SGD","LU0889565916.HKD","IE00BFSS7M15.SGD","LU1069344957.HKD","SG9999015978.USD","IE00B1XK9C88.USD","LU2063271972.USD","LU2112291526.USD","LU1093756168.USD","LU1868836914.USD","LU0823416689.USD","IE0009355771.USD","LU0097036916.USD","LU2271345857.HKD","LU2357305700.SGD","BK4007","BK4585","LU0058720904.USD","IE00B1BXHZ80.USD","LU0256863811.USD","LU1868836757.USD","IE00BN29S564.USD","LU2324357040.USD","LU1548497426.USD","LU0266013472.USD","LU1814569148.SGD","SG9999001176.USD","BK4599","LU2468319806.SGD","LU2023251221.USD","LU2213496289.HKD","SGXZ81514606.USD","LU1629891620.HKD","LU1145028129.USD","SG9999014880.SGD","LU0456855351.SGD","IE0005OL40V9.USD","LLYX","LU0882574139.USD","LU0471298777.SGD","LU1868837300.USD","IE00BK4W5L77.USD"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0119},{"period":"3month","weight":-0.0064},{"period":"6month","weight":0.0526},{"period":"1year","weight":0.1685},{"period":"ytd","weight":-0.0009}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"制药","nameEN":"BK4007"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"制药,BK4007,制药股票,制药股票老虎,制药股票老虎国际,制药行情,制药股票行情,制药股价,制药股市,制药股票价格,制药股票交易,制药股票购买,制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"制药(BK4007)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供制药(BK4007)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}